Replies to post #4100 on Ayala Pharmaceuticals Inc (ADXS)

[James salmon]

I think its important to keep in mind that people are still dying even after PD1 treatment. OS is around 7.5 months on this trial. If you go look at preclinical work done with PD1 and LM combined, there is a major difference in survival rate.

Finding something that when combined with PD1 will have even greater efficiency than PD1 on its own, is the goal, and if Advaxis platform has same efficiency that it has shown in preclinical, then it will be a game changer.